Ser327

Site Information
AEAEGGVsDSLEDIE SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 25752183

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 )
Relevant cell line - cell type - tissue:	BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 )

References
1	Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32 28852199 Curated Info
2	Guo A (2007) CST Curation Set: 3619; Year: 2007; Biosample/Treatment: cell line, E1-1796/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS/T) Immunoaffinity Beads Cat#: 1978 Curated Info

References

Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32
28852199 Curated Info

Guo A (2007) CST Curation Set: 3619; Year: 2007; Biosample/Treatment: cell line, E1-1796/rapamycin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info